Adjuvant taxanes and the development of breast cancer-related arm lymphoedema.
Identifieur interne : 000E55 ( PubMed/Corpus ); précédent : 000E54; suivant : 000E56Adjuvant taxanes and the development of breast cancer-related arm lymphoedema.
Auteurs : M. Cariati ; S K Bains ; M R Grootendorst ; A. Suyoi ; A M Peters ; P. Mortimer ; P. Ellis ; M. Harries ; M. Van Hemelrijck ; A D PurushothamSource :
- The British journal of surgery [ 1365-2168 ] ; 2015.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Agents (adverse effects), Arm, Axilla, Breast Neoplasms (drug therapy), Breast Neoplasms (surgery), Chemotherapy, Adjuvant, Cohort Studies, Female, Humans, Lymph Node Excision, Lymphedema (chemically induced), Mastectomy, Middle Aged, Postoperative Complications (chemically induced), Proportional Hazards Models, Retrospective Studies, Risk Factors, Taxoids (adverse effects), Treatment Outcome.
- MESH :
- chemical , adverse effects : Antineoplastic Agents, Taxoids.
- chemically induced : Lymphedema, Postoperative Complications.
- drug therapy : Breast Neoplasms.
- surgery : Breast Neoplasms.
- Adult, Aged, Arm, Axilla, Chemotherapy, Adjuvant, Cohort Studies, Female, Humans, Lymph Node Excision, Mastectomy, Middle Aged, Proportional Hazards Models, Retrospective Studies, Risk Factors, Treatment Outcome.
Abstract
Despite affecting approximately one-quarter of all patients undergoing axillary lymph node dissection, the pathophysiology of breast cancer-related lymphoedema (BCRL) remains poorly understood. More extensive locoregional treatment and higher body mass index have long been identified as major risk factors. This study aimed to identify risk factors for BCRL with a specific focus on the potential impact of chemotherapy on the risk of BCRL.
DOI: 10.1002/bjs.9846
PubMed: 26040263
Links to Exploration step
pubmed:26040263Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adjuvant taxanes and the development of breast cancer-related arm lymphoedema.</title><author><name sortKey="Cariati, M" sort="Cariati, M" uniqKey="Cariati M" first="M" last="Cariati">M. Cariati</name><affiliation><nlm:affiliation>Section of Research Oncology, King's College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Bains, S K" sort="Bains, S K" uniqKey="Bains S" first="S K" last="Bains">S K Bains</name><affiliation><nlm:affiliation>Section of Research Oncology, King's College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Grootendorst, M R" sort="Grootendorst, M R" uniqKey="Grootendorst M" first="M R" last="Grootendorst">M R Grootendorst</name><affiliation><nlm:affiliation>Section of Research Oncology, King's College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Suyoi, A" sort="Suyoi, A" uniqKey="Suyoi A" first="A" last="Suyoi">A. Suyoi</name><affiliation><nlm:affiliation>Directorate of Haematology and Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Peters, A M" sort="Peters, A M" uniqKey="Peters A" first="A M" last="Peters">A M Peters</name><affiliation><nlm:affiliation>Department of Nuclear Medicine, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Mortimer, P" sort="Mortimer, P" uniqKey="Mortimer P" first="P" last="Mortimer">P. Mortimer</name><affiliation><nlm:affiliation>Department of Clinical Sciences, St George's, University of London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Ellis, P" sort="Ellis, P" uniqKey="Ellis P" first="P" last="Ellis">P. Ellis</name><affiliation><nlm:affiliation>Section of Research Oncology, King's College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Harries, M" sort="Harries, M" uniqKey="Harries M" first="M" last="Harries">M. Harries</name><affiliation><nlm:affiliation>Section of Research Oncology, King's College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Van Hemelrijck, M" sort="Van Hemelrijck, M" uniqKey="Van Hemelrijck M" first="M" last="Van Hemelrijck">M. Van Hemelrijck</name><affiliation><nlm:affiliation>School of Medicine, Cancer Epidemiology Group, Division of Cancer Studies, King's College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Purushotham, A D" sort="Purushotham, A D" uniqKey="Purushotham A" first="A D" last="Purushotham">A D Purushotham</name><affiliation><nlm:affiliation>Section of Research Oncology, King's College London, London, UK.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26040263</idno><idno type="pmid">26040263</idno><idno type="doi">10.1002/bjs.9846</idno><idno type="wicri:Area/PubMed/Corpus">000E55</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E55</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Adjuvant taxanes and the development of breast cancer-related arm lymphoedema.</title><author><name sortKey="Cariati, M" sort="Cariati, M" uniqKey="Cariati M" first="M" last="Cariati">M. Cariati</name><affiliation><nlm:affiliation>Section of Research Oncology, King's College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Bains, S K" sort="Bains, S K" uniqKey="Bains S" first="S K" last="Bains">S K Bains</name><affiliation><nlm:affiliation>Section of Research Oncology, King's College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Grootendorst, M R" sort="Grootendorst, M R" uniqKey="Grootendorst M" first="M R" last="Grootendorst">M R Grootendorst</name><affiliation><nlm:affiliation>Section of Research Oncology, King's College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Suyoi, A" sort="Suyoi, A" uniqKey="Suyoi A" first="A" last="Suyoi">A. Suyoi</name><affiliation><nlm:affiliation>Directorate of Haematology and Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Peters, A M" sort="Peters, A M" uniqKey="Peters A" first="A M" last="Peters">A M Peters</name><affiliation><nlm:affiliation>Department of Nuclear Medicine, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Mortimer, P" sort="Mortimer, P" uniqKey="Mortimer P" first="P" last="Mortimer">P. Mortimer</name><affiliation><nlm:affiliation>Department of Clinical Sciences, St George's, University of London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Ellis, P" sort="Ellis, P" uniqKey="Ellis P" first="P" last="Ellis">P. Ellis</name><affiliation><nlm:affiliation>Section of Research Oncology, King's College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Harries, M" sort="Harries, M" uniqKey="Harries M" first="M" last="Harries">M. Harries</name><affiliation><nlm:affiliation>Section of Research Oncology, King's College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Van Hemelrijck, M" sort="Van Hemelrijck, M" uniqKey="Van Hemelrijck M" first="M" last="Van Hemelrijck">M. Van Hemelrijck</name><affiliation><nlm:affiliation>School of Medicine, Cancer Epidemiology Group, Division of Cancer Studies, King's College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Purushotham, A D" sort="Purushotham, A D" uniqKey="Purushotham A" first="A D" last="Purushotham">A D Purushotham</name><affiliation><nlm:affiliation>Section of Research Oncology, King's College London, London, UK.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The British journal of surgery</title><idno type="eISSN">1365-2168</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antineoplastic Agents (adverse effects)</term><term>Arm</term><term>Axilla</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (surgery)</term><term>Chemotherapy, Adjuvant</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Lymph Node Excision</term><term>Lymphedema (chemically induced)</term><term>Mastectomy</term><term>Middle Aged</term><term>Postoperative Complications (chemically induced)</term><term>Proportional Hazards Models</term><term>Retrospective Studies</term><term>Risk Factors</term><term>Taxoids (adverse effects)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term><term>Taxoids</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Lymphedema</term><term>Postoperative Complications</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Arm</term><term>Axilla</term><term>Chemotherapy, Adjuvant</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Lymph Node Excision</term><term>Mastectomy</term><term>Middle Aged</term><term>Proportional Hazards Models</term><term>Retrospective Studies</term><term>Risk Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Despite affecting approximately one-quarter of all patients undergoing axillary lymph node dissection, the pathophysiology of breast cancer-related lymphoedema (BCRL) remains poorly understood. More extensive locoregional treatment and higher body mass index have long been identified as major risk factors. This study aimed to identify risk factors for BCRL with a specific focus on the potential impact of chemotherapy on the risk of BCRL.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26040263</PMID><DateCreated><Year>2015</Year><Month>07</Month><Day>15</Day></DateCreated><DateCompleted><Year>2015</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2015</Year><Month>07</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2168</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>9</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The British journal of surgery</Title><ISOAbbreviation>Br J Surg</ISOAbbreviation></Journal><ArticleTitle>Adjuvant taxanes and the development of breast cancer-related arm lymphoedema.</ArticleTitle><Pagination><MedlinePgn>1071-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/bjs.9846</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite affecting approximately one-quarter of all patients undergoing axillary lymph node dissection, the pathophysiology of breast cancer-related lymphoedema (BCRL) remains poorly understood. More extensive locoregional treatment and higher body mass index have long been identified as major risk factors. This study aimed to identify risk factors for BCRL with a specific focus on the potential impact of chemotherapy on the risk of BCRL.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a retrospective analysis of a cohort of consecutive patients with breast cancer treated at a major London regional teaching hospital between 1 January 2010 and 31 December 2012. All patients had node-positive disease and underwent axillary lymph node dissection. Data regarding tumour-, patient- and treatment-related characteristics were collected prospectively. The diagnosis of BCRL was based on both subjective and objective criteria. Multivariable Cox proportional hazards regression was used to assess the association between treatment and risk of BCRL.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Some 27.1 per cent of all patients (74 of 273) developed BCRL over the study period. Administration of taxanes showed a strong association with the development of BCRL, as 52 (33.5 per cent) of 155 patients who received taxanes developed BCRL. Multivariable Cox regression analysis demonstrated that patients who received taxanes were nearly three times more likely to develop BCRL than patients who had no chemotherapy (hazard ratio 2.82, 95 per cent c.i. 1.31 to 6.06). No such increase was observed when taxanes were administered in the neoadjuvant setting.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The present findings suggest that adjuvant taxanes play a key role in the development of BCRL after surgery. This may support the use of taxanes in a neoadjuvant rather than adjuvant setting.</AbstractText><CopyrightInformation>© 2015 BJS Society Ltd Published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cariati</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Research Oncology, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Directorate of Haematology and Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bains</LastName><ForeName>S K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Section of Research Oncology, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grootendorst</LastName><ForeName>M R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Section of Research Oncology, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suyoi</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Directorate of Haematology and Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mortimer</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, St George's, University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Section of Research Oncology, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Directorate of Haematology and Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harries</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Research Oncology, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Directorate of Haematology and Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Hemelrijck</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Medicine, Cancer Epidemiology Group, Division of Cancer Studies, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purushotham</LastName><ForeName>A D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Section of Research Oncology, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Directorate of Haematology and Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Studies</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Surg</MedlineTA><NlmUniqueID>0372553</NlmUniqueID><ISSNLinking>0007-1323</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043823">Taxoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001132" MajorTopicYN="N">Arm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001365" MajorTopicYN="N">Axilla</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008408" MajorTopicYN="Y">Mastectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043823" MajorTopicYN="N">Taxoids</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>09</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>02</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>04</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26040263</ArticleId><ArticleId IdType="doi">10.1002/bjs.9846</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000E55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26040263
|texte= Adjuvant taxanes and the development of breast cancer-related arm lymphoedema.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26040263" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |